Ma Wenxue, Baran Natalia
Department of Medicine, Sanford Stem Cell Institute, Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, United States.
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
World J Clin Oncol. 2025 Apr 24;16(4):104213. doi: 10.5306/wjco.v16.i4.104213.
This editorial provides insights into the pivotal role of checkpoint kinase 1 (CHEK1) as both a biomarker and therapeutic target in colorectal cancer (CRC), based on findings from a recent study by Pang . Using single-cell RNA sequencing and immunohistochemistry, the study demonstrates significant CHEK1 overexpression in CRC tissues and identifies nitidine chloride as a potent CHEK1 inhibitor that disrupts DNA damage repair pathways. These findings underscore the therapeutic potential of CHEK1 inhibition and highlight the need for further research to address gaps in CRC treatment.
基于庞最近的一项研究结果，这篇社论深入探讨了检查点激酶1（CHEK1）作为生物标志物和治疗靶点在结直肠癌（CRC）中的关键作用。该研究使用单细胞RNA测序和免疫组织化学方法，证明了CHEK1在CRC组织中显著过表达，并确定氯化两面针碱为一种有效的CHEK1抑制剂，可破坏DNA损伤修复途径。这些发现强调了抑制CHEK1的治疗潜力，并突出了进一步研究以填补CRC治疗空白的必要性。
